We’re Challenging the Status Quo in Cancer Treatment

Scientific curiosity enables Aprea to make breakthroughs designed to address the significant unmet therapeutic needs of patients with certain genetically defined cancers.

Almost everyone has been impacted by cancer, either personally or through a loved one, which is why we’re passionate about changing the status quo. Our commitment to saving lives drives us to explore approaches that haven’t been tried–or even thought of–before.

Over a decade ago, our team was the first to recognize the DDR gene, ATR, as a potential target for precision cancer therapeutics. And we continue to forge new paths. Today, Aprea Therapeutics is a clinical-stage biotechnology company focused on the development of novel, synthetic lethality-based therapies with direct on-target mechanisms of action and clear clinical pathways.

Our acquisition of Atrin Pharmaceuticals supports our latest innovations in targeted oncology approaches.

Aprea Therapeutics acquired privately held Atrin Pharmaceuticals in May 2022 and has moved ATRN-119 and APR-1051 forward.